The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

"We believe QUTENZA® may be a clinically meaningful treatment option that could address the unmet needs of many patients in the United States who suffer from Post-surgical neuropathic pain and may not ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...